- Home
- OABI vs KOD Comparison
OABI vs KOD Comparison
Compare OABI & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- KOD
- Stock Information
- Founded
- OABI 2012
- KOD 2009
- Country
- OABI United States
- KOD United States
- Employees
- OABI N/A
- KOD N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OABI Health Care
- KOD Health Care
- Exchange
- OABI Nasdaq
- KOD Nasdaq
- Market Cap
- OABI 389.7M
- KOD 454.7M
- IPO Year
- OABI N/A
- KOD 2018
- Fundamental
- Price
- OABI $3.65
- KOD $4.45
- Analyst Decision
- OABI Strong Buy
- KOD Hold
- Analyst Count
- OABI 4
- KOD 4
- Target Price
- OABI $9.00
- KOD $8.00
- AVG Volume (30 Days)
- OABI 569.4K
- KOD 347.2K
- Earning Date
- OABI 03-19-2025
- KOD 03-27-2025
- Dividend Yield
- OABI N/A
- KOD N/A
- EPS Growth
- OABI N/A
- KOD N/A
- EPS
- OABI N/A
- KOD N/A
- Revenue
- OABI $20,409,000.00
- KOD N/A
- Revenue This Year
- OABI N/A
- KOD N/A
- Revenue Next Year
- OABI $78.61
- KOD N/A
- P/E Ratio
- OABI N/A
- KOD N/A
- Revenue Growth
- OABI N/A
- KOD N/A
- 52 Week Low
- OABI $3.10
- KOD $2.19
- 52 Week High
- OABI $6.55
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- OABI 53.96
- KOD 27.56
- Support Level
- OABI $3.61
- KOD $4.85
- Resistance Level
- OABI $4.02
- KOD $5.53
- Average True Range (ATR)
- OABI 0.18
- KOD 0.39
- MACD
- OABI 0.04
- KOD -0.05
- Stochastic Oscillator
- OABI 58.89
- KOD 1.03
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.